Tracing the ghost in the blockchain’s memory.
Over the past 12 months, the GLP-1 weight-loss market has seen its most dramatic narrative shift since the approval of semaglutide in 2021. On January 10, 2025, Novo Nordisk’s CEO, Lars Fruergaard Jørgensen, told investors that the company’s oral Wegovy had already generated over 5 million prescriptions since its launch just six months prior. The stock dropped 6% that same day.
This is the kind of cognitive dissonance that my cybersecurity background trained me to spot: a protocol with strong on-chain metrics (prescriptions, user growth) gets punished by the market because the market is pricing in a future that hasn’t happened yet.
Where liquidity flows, stories drown.
Let’s rewind the tape. The GLP-1 market is not a single token — it’s a multi-chain ecosystem with two dominant L1s: Novo Nordisk and Eli Lilly. Both have issued their own native assets (weight-loss drugs) and are competing for the same finite pool of users (obese and overweight patients). The total addressable market is enormous — over 10 billion people globally are overweight or obese — but the real bottleneck is not demand; it’s supply, distribution, and payer coverage.
To understand the current narrative tension, we need to look at the underlying mechanics. Novo’s oral Wegovy (semaglutide, delivered via a SNAC absorption enhancer) is a Me-better innovation: it extends the injectable Wegovy’s indication into an oral form factor, offering convenience and compliance. Lilly’s tirzepatide (Mounjaro/Zepbound) is a Best-in-class dual GIP/GLP-1 receptor agonist that has shown 20%+ weight loss in SURMOUNT trials, beating semaglutide’s 15-17% on a head-to-head basis (though cross-trial comparisons are noisy).
But the real narrative war isn’t about efficacy alone — it’s about protocol defensibility, patient lock-in, and the cost of switching. In blockchain terms, Novo has first-mover advantage in the oral layer, but Lilly’s orforglipron (a small-molecule oral GLP-1, non-peptide) is a potential Ethereum-killer: cheaper to manufacture, no cold chain, and scalable without the SNAC patent. If orforglipron gains FDA approval by 2026-2027, it could disrupt Novo’s oral advantage entirely.
Minting moments that outlast the cycle.
Based on my experience auditing smart contracts during the 2017 ICO boom, I’ve learned that the most compelling narratives often hide the most critical vulnerabilities. In the GLP-1 space, the vulnerability is pricing power. Both Novo and Lilly are lowering net prices to gain volume, but the trade-off is brutal: halve the price, double the prescriptions just to break even. Novo’s CEO admitted in a recent interview that Lilly has been more successful in capturing market share. The data from IQVIA shows that Zepbound’s new prescription volume has occasionally surpassed Wegovy’s.
But here’s the contrarian angle: the market is over-pricing the risk of IRA drug price negotiations (the U.S. Inflation Reduction Act allows Medicare to negotiate prices for selected drugs, and GLP-1s are prime candidates). The article I analyzed completely omitted the IRA — a classic blind spot. The real impact of IRA on Novo’s revenue is likely to be phased in over 2027-2029, not tomorrow. Meanwhile, oral Wegovy’s 5 million prescriptions in six months is a real-world signal that the oral form factor is unlocking a new user segment — patients who refused injections.
The chaos was the curriculum.
Let me walk you through the numbers with the rigor of a cybersecurity audit. The article claims that Novo’s oral pill shows 17% weight loss vs. Lilly’s 12% (based on company-stated cross-trial comparisons). But as any auditor knows, cross-trial comparisons are like comparing two different blockchains with different consensus mechanisms — patient baselines, background lifestyle interventions, and trial durations differ. The 17% figure comes from Novo’s own trial, while Lilly’s 12% likely comes from a different dose or patient population. The real head-to-head will come from the CagriSema (Novo’s combination of cagrilintide + semaglutide) vs. Zepbound trials expected in 2025-2026.
Another hidden layer: the patent cliff. Semaglutide’s core patents expire in the early 2030s, but the oral formulation patents extend to mid-2030s. However, small-molecule GLP-1s like orforglipron could bypass those patents entirely. This is analogous to a protocol that has a patent on its consensus mechanism but a new layer-2 solution comes along with a different approach.
Parsing truth from the noise of new value.
What about the Chinese market? The article correctly notes that China has 200 million obese individuals, but Novo’s Wegovy was approved for weight loss in China in 2024, and Lilly’s tirzepatide is under review. But the real story is the Chinese generic threat: companies like Huadong Medicine, Hengrui, and Innovent are developing biosimilars and novel GLP-1 drugs (e.g., mazdutide) that could launch at 30-50% lower prices. This is a classic “unlucky for the incumbent” scenario — the Chinese market could decouple from global pricing, forcing Novo and Lilly to compete on volume in a low-margin environment.
Visuals are the new vernacular.
Let’s visualize the competitive landscape as a matrix. On one axis, delivery form (injectable vs. oral vs. small molecule). On the other, mechanism of action (single GLP-1, dual GIP/GLP-1, triple GIP/GLP-1/glucagon). Novo dominates the oral form with its SNAC platform, but Lilly is building a superior small-molecule pipeline. The next two years will determine whether Novo can maintain its lead or whether Lilly’s multi-pronged approach (orforglipron, retatrutide, triple agonists) will create a winner-takes-most dynamic.
Finding the human pulse in algorithmic loops.
From a narrative strategy perspective, the market is currently re-pricing Novo’s risk premium. The stock has fallen from its 2024 highs partly because of the CagriSema Phase III disappointment in December 2024 (REDEFINE program missed consensus expectations, knocking the stock 20% in one day). That event is a classic “black swan” that the original article failed to mention. Yet, the oral Wegovy prescription data is a strong counter-narrative: if the trend continues, Novo could see revenue from oral Wegovy alone reach $100-150 billion by 2030, offsetting pricing pressure.
But here’s the key insight: the market is not stupid. It’s pricing in a future where pricing power erodes faster than volume growth. The 5 million prescriptions figure is impressive, but we don’t know how many are self-pay vs. insurance-covered, nor the persistence rate (only 30-40% of patients stay on GLP-1 therapy for 12 months based on real-world data). The net retention rate is the true “churn” metric that matters.
The contrarian takeaway: The real winner in the GLP-1 narrative war may not be Novo or Lilly, but the payer ecosystem — insurance companies, PBMs, and the government. As competition intensifies, net prices will fall, making GLP-1s more accessible. This will expand the total addressable market, but compress margins for drug manufacturers. The next narrative shift will come from Medicare coverage of obesity drugs (a CMS rule change likely in 2025-2026) or from AI-driven drug discovery that accelerates the next generation of small-molecule GLP-1s.
The chaos was the curriculum.
In my consulting work, I often tell clients that narratives are like liquidity pools — they flow to where the return is highest. Right now, the return is highest in the oral GLP-1 space, but the long-term alpha is in the small-molecule pipeline. Investors who treat this as a simple “two-horse race” are missing the structural shift: the entry of Chinese generics, the impact of IRA, and the potential of AI to compress drug development timelines.
Minting moments that outlast the cycle.
The next 12 months will be pivotal. Watch for: (1) orforglipron Phase III data, (2) CagriSema final readout, (3) CMS decision on Medicare coverage for obesity, and (4) Chinese biosimilar approvals. The protocol that wins the narrative will be the one that addresses the core pain point: not efficacy, but accessibility. The market is already telling us that.
As I always say, tracing the ghost in the blockchain’s memory reveals that the most valuable data is often the data that’s missing. In this case, the missing data is the true net price trajectory and the patient retention rates. Those are the metrics that will determine whether Novo’s oral Wegovy is a game-changer or a temporary spike.
Where liquidity flows, stories drown. But the story of GLP-1 is far from over. The next chapter is being written in the small-molecule labs of Lilly, the CVD outcome trials of Novo, and the regulatory halls of the CMS. Stay tuned.
